跳至主要内容
临床试验/CTRI/2019/03/018112
CTRI/2019/03/018112已完成2/3 期

An interventional comparative clinical study on Guduchyadi Karma Basti and Rasayana Avaleha in the management of Cancer W.S.R. Gastro-intestinal cancer

IPGT and RA GAU jamnagar1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2019年3月20日最近更新:

试验速览

阶段
2/3 期
状态
已完成
发起方
入组人数
30
试验地点
1
主要终点
efficacy

研究概览

简要总结

This study is An randomized Interventional Comparative Clinical trial to evaluate the effect of Guduchyadi Karma Basti and Rasayana Avaleha in the Management of Cancer w.s.r. Gastro-intestinal Cancer. total 30patients will be enrolled in present study. Selected patients will be divided in three group on the basis of computer generated randomisation. in this study in group A Guduchyadi Karma Basti which is combination of Guduchi Ghrita Anuvasana Basti(100ml to 120ml ) and Guduchyadi Niruha Basti(600ml to 900ml) will be given though rectal route for 30 day in alternate day pattern and in group B Guduchyadi Karma Bastiwhich is combination of Guduchi Ghrita Anuvasana Basti(100ml to 120ml ) and Guduchyadi Niruha Basti(600ml to 900ml) will be given though rectal route for 30 day in alternate day pattern with Rasayana Avaleha  30gm per day for 30 day will be given and efficacy compared with palliative conservative medicine for cancer treatment or in follow up in cancer treatment.

Conclusion

·        Guduchyadi Karma Basti with Rasayana**Avaleha are better management for cancer patients to improving theirQuality of life.

·        Guduchyadi Karma Basti with Rasayana**Avaleha shows better management for cancer patients to reducing chiefcomplaint like Nusea, vomiting, Dysphasia constipation, fatigue abdominal pain,localized pain and loss of appetite.

·        Guduchyadi Karma Basti with Rasayana**Avaleha able to pacify Urinary tract infection by reducing pus cell,epithelial cell and albumin from urine

·        Guduchyadi Karma Basti with Rasayana**Avaleha more cost effective rather than other conventional moderntreatment and able to reduce economic burden of cancer patients and theirfamily

·        Thus, it is concludedthat Null hypothesis H0 and Alternative hypothesis H1 is rejected. WhileAlternative hypothesis H2 is accepted.

研究设计

研究类型
Interventional
分配方式
Computer generated randomization
盲法
Open Label

入排标准

年龄范围
18.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • Patients with histopathologically proved diagnosed as 1st and 2nd stage of Gastro-intestinal Cancer From oral cavity to large intestine Patients who are suitable for Basti Karma Willing and able to participate in the study.

排除标准

  • Patients diagnosed as 3rd and 4th stage of cancer of any type Chronic long term local adverse effects.
  • Known cases of hypertension or ischemic heart disease and acute infection etc Patients with ano-rectal carcinoma Cachexic or terminally ill patients.

结局指标

主要结局

efficacy

时间窗: prospective

次要结局

  • Safety(prospective)

研究者

发起方
IPGT and RA GAU jamnagar
申办方类型
Research institution and hospital

研究点 (1)

Loading locations...

相似试验